TY - JOUR
T1 - Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?
AU - Endimiani, Andrea
AU - Hujer, Kristine M.
AU - Hujer, Andrea M.
AU - Kurz, Sebastian
AU - Jacobs, Michael R.
AU - Perlin, David S.
AU - Bonomo, Robert A.
N1 - Funding Information:
Supplement sponsorship. This article was published as part of a supplement entitled ‘‘Workshop on Molecular Diagnostics for Respiratory Tract Infections.’’ The Food and Drug Administration and the Infectious Diseases Society of America sponsored the workshop. AstraZeneca Pharmaceuticals, Bio Merieux, Inc., Cepheid, Gilead Sciences, Intelligent MDX, Inc., Inverness Medical Innovations, and Roche Molecular Systems provided financial support solely for the purpose of publishing the supplement.
Funding Information:
Financial support. This work was supported by the Veterans Affairs Merit Review Program (R. A. B.); the National Institutes of Health (grants R01-AI063517, R03-AI081036, and R01-AI072219 to R. A. B.); and the Geriatric Research Education and Clinical Center VISN 10 (R. A. B.). Dr. Perlin is supported by the National Institutes of Health.
Funding Information:
Potential conflicts of interest. R. A. B. is a recipient of a research grant from Pfizer and Steris Corporation and has collaborated with Ibis Biosciences and Abbott Molecular, Inc., on publications in the screening of bacterial isolates. D. S. P. receives grant support from Merck, Pfizer, As-tellas, Celgene, bioMerieux, and the National Institutes of Health and serves on advisory boards for Merck, Pfizer, Astellas, and Myconostica. All other authors: no conflicts.
PY - 2011/5/1
Y1 - 2011/5/1
N2 - Hospital-acquired pneumonia represents one of the most difficult treatment challenges in infectious diseases. Many studies suggest that the timely administration of appropriate, pathogen-directed therapy can be lifesaving. Because results of culture and antimicrobial susceptibility testing can take 48 h or longer, physicians currently rely on clinical, epidemiological, and demographic factors to assist with the choice of empiric therapy for antibiotic-resistant pathogens. At present, a number of rapid molecular tests are being developed that identify pathogens and the presence of genetic determinants of antimicrobial resistance (eg, GeneXpert [Cepheid], ResPlex [Qiagen], FilmArray [Idaho Technologies], and Microarray [Check-Points]). In this review, the potential impact that molecular diagnostics has to identify and characterize pathogens that cause hospital-acquired bacterial pneumonia at an early stage is examined. In addition, a perspective on a novel technology, polymerase chain reaction followed by electrospray ionization mass spectrometry, is presented, and its prospective use in the diagnosis of pneumonia is also discussed. The complexities of the pulmonary microbiome represent a novel challenge to clinicians, but many questions still remain even as these technologies improve.
AB - Hospital-acquired pneumonia represents one of the most difficult treatment challenges in infectious diseases. Many studies suggest that the timely administration of appropriate, pathogen-directed therapy can be lifesaving. Because results of culture and antimicrobial susceptibility testing can take 48 h or longer, physicians currently rely on clinical, epidemiological, and demographic factors to assist with the choice of empiric therapy for antibiotic-resistant pathogens. At present, a number of rapid molecular tests are being developed that identify pathogens and the presence of genetic determinants of antimicrobial resistance (eg, GeneXpert [Cepheid], ResPlex [Qiagen], FilmArray [Idaho Technologies], and Microarray [Check-Points]). In this review, the potential impact that molecular diagnostics has to identify and characterize pathogens that cause hospital-acquired bacterial pneumonia at an early stage is examined. In addition, a perspective on a novel technology, polymerase chain reaction followed by electrospray ionization mass spectrometry, is presented, and its prospective use in the diagnosis of pneumonia is also discussed. The complexities of the pulmonary microbiome represent a novel challenge to clinicians, but many questions still remain even as these technologies improve.
UR - http://www.scopus.com/inward/record.url?scp=79953787256&partnerID=8YFLogxK
U2 - 10.1093/cid/cir054
DO - 10.1093/cid/cir054
M3 - Article
C2 - 21460299
AN - SCOPUS:79953787256
SN - 1058-4838
VL - 52
SP - S373-S383
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 4
ER -